Trial Profile

FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN -BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIAS PATIENTS AT FIRST RELAPSE

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
Indications Waldenstrom's macroglobulinaemia
Focus Therapeutic Use
Acronyms FIL_BRB

Most Recent Events

01 Feb 2025 Results published in the British Journal of Haematology
14 Dec 2021 Final results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
01 Dec 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com